

**From:** [OC GCP Questions](#)  
**To:** [REDACTED]  
**Cc:** [CDER DRUG INFO](#)  
**Subject:** Pharmacy and Laboratory Temperatures  
**Date:** Tuesday, July 15, 2014 10:01:01 AM

---

Good morning Ž^â&^âá

It is acceptable to transfer to an electronic system from paper. And yes you should work with the sponsor to make sure they are involved. An electronic data capture system for FDA-regulated studies should be Part 11 compliant. FDA's regulations for electronic records and electronic signature can be found at 21 CFR Part 11 (<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcr/CFRSearch.cfm?CFRPart=11>). Part 11 applies to records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under any records requirements set forth in Agency regulations, as well as electronic records submitted to the Agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, even if such records are not specifically identified in Agency regulations.

I've listed below a few FDA guidance documents that you may find helpful:

FDA's Guidance for Industry – Computerized Systems Used in Clinical Investigations found at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070266.pdf>

FDA's Draft Guidance for Industry – Electronic Source Data in Clinical Investigations found at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM328691.pdf>

FDA's Guidance for Industry -- Part 11, Electronic Records; Electronic Signatures --Scope and Application found at <http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126953.pdf>

For you second question, FDA regulations require very few signatures and the timeframe for a PI to sign off on information is also not addressed in FDA regulations. Therefore, as you state, and SOP would be appropriate in this situation.

I hope this information is helpful. Please contact us again at [gcp.questions@fda.hhs.gov](mailto:gcp.questions@fda.hhs.gov) should you have additional questions.

Doreen M. Kezer, MSN  
Senior Health Policy Analyst  
Office of Good Clinical Practice  
Office of the Commissioner, FDA

This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

---

**From:** CDER DRUG INFO  
**Sent:** Monday, July 07, 2014 4:58 PM  
**To:** OC GCP Questions  
**Subject:** FW: Pharmacy and Laboratory Temperatures

Hi GCP,

Can you help us with the questions below? Please let me know if this should go somewhere else instead.

Thanks so much!

Cherryn

Cherryn Chang, Pharm.D.  
Division of Drug Information  
FDA/CDER/OCOMM

---

**From:** ~~CFYXUMWXQ~~  
**Sent:** Monday, July 07, 2014 4:12 PM  
**To:** CDER DRUG INFO  
**Cc:** ~~CFYXUMWXQ~~  
**Subject:** Pharmacy and Laboratory Temperatures

To whom it may concern:

We are in the process of switching to an online managed electronic temperature monitoring device for our pharmacy and laboratory. We are able to download the temperatures (maintained daily) to a CD/DVD instead of printing them. We normally have a print out of the temperatures for the duration of the clinical trial, but would like to just have a DVD or CD. Is this allowed? Or do we need to complete additional electronic paperwork to maintain our logs electronically? Or is this up to the Sponsors that we directly work with?

The second issue I wanted to just confirm is lab and ECG result signing. When we receive the subjects lab and ECG reports, our PI or MDs sign off on them. Is there a required timeframe of when they have to sign off? Or is it just per our SOPs or practice?

I appreciate your time and please let me know if you need more information.

Thanks in advance,

~~CFYXUMWXQ~~